Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23269745 | 0.74 | NAMPT (0.38) | NAMPTCA12CA1CA9 | |
| SCHEMBL24406166 | 0.74 | NAMPT (0.35) | NAMPTCA12CA1CA9 | |
| SCHEMBL968065 | 0.74 | CA12 (0.32) | CA12CA9 | |
| SCHEMBL965808 | 0.73 | NAMPT (0.35) | NAMPTCA12CA1CA9 | |
| SCHEMBL497808 | 0.70 | CA12 (0.36) | NAMPTCA12CA1CA9 | |
| SCHEMBL6207217 | 0.70 | MEN1 (0.38) | NAMPTCA12CA1CA9 | |
| SCHEMBL6207215 | 0.70 | CA12 (0.36) | NAMPTCA12CA1CA9 | |
| SCHEMBL18125071 | 0.69 | CA1 (0.37) | NAMPTCA12CA1CA9 | |
| SCHEMBL10964801 | 0.69 | NAMPT (0.35) | NAMPTCA12CA1CA9 | |
| SCHEMBL25007406 | 0.69 | CA12 (0.34) | NAMPTCA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7867992-B2 | such as 1-Cyclopropyl-N-(2,4-dichlorobenzyl)-6-fluoro-8-methoxy-7-[3-methyl-4-(2-{[(methylamino)carbonyl]amino}-2-oxoethyl)piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxamide, used for the treatment and/or prophylaxis of viral diseases or infections, particularly against cytomegaloviruses | AICURIS GMBH & CO. KG (DE) | 2011-01-11 | — | — | US | disclosed |
| US-20070293478-A1 | Substituted quinolones | BAYER HEALTHCARE AG (DE) | 2007-12-20 | — | — | US | disclosed |
| EP-1770091-A1 | CGRP-antagonists, process for their preparation as well as their use as medicaments | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-04-04 | — | — | EP | disclosed |
| EP-1770087-A1 | Selected CGRP antagonists, process for their preparation as well as their use as medicaments | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293478-A1 | Substituted quinolones | IRF3, TPMT, NQO2 | NAMPT 359/4885CA12 2872/4885CA1 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.